Astrana Health, Inc. (NASDAQ:ASTH) Receives $56.17 Average Target Price from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $56.17.

ASTH has been the subject of a number of analyst reports. Robert W. Baird cut their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Bank of America cut their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Truist Financial decreased their target price on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Stifel Nicolaus cut their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Finally, Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new position in Astrana Health during the 3rd quarter valued at about $1,164,000. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health in the third quarter valued at approximately $13,383,000. Franklin Resources Inc. purchased a new position in shares of Astrana Health during the 3rd quarter worth approximately $1,187,000. Geode Capital Management LLC acquired a new position in shares of Astrana Health during the 3rd quarter worth approximately $58,995,000. Finally, HighTower Advisors LLC purchased a new stake in Astrana Health in the 3rd quarter valued at approximately $5,799,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Price Performance

Shares of NASDAQ:ASTH opened at $30.54 on Thursday. Astrana Health has a one year low of $23.12 and a one year high of $63.20. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 1.37 and a beta of 1.30. The company has a 50-day simple moving average of $33.85 and a 200-day simple moving average of $41.94. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $665.21 million for the quarter, compared to analysts’ expectations of $617.24 million. On average, analysts predict that Astrana Health will post 1.15 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.